Sign in to view content

Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials

Katherine E Talcott, MD

Video
Published 2021

Related

Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Updates from the Field
2022
Bevacizumab-First vs Real-World Cost Outcomes for Diabetic Macular Edema: 2-Year Cost Analysis Modeled on DRCR Protocol AC Results
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2023
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial
John W. Kitchens, MD
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more